Dr. Kelley on the Development of Biomarkers for HCC
R. Kate Kelley, MD, associate professor, University of California, San Francisco, discusses the development of biomarkers for patients with hepatocellular carcinoma (HCC).
The potential of many therapies in development depends on identifying the patient groups most likely to benefit, explains Kelley. This will require a better understanding of the biology of HCC.
According to Kelley, the potential of new therapies will drive a wave of research to further define the relevant subgroups.